阿奇霉素二水合物市场－全球产业规模、份额、趋势、机会、预测：按产品、应用、地区和竞争对手划分，2021-2031年

全球二水合氨霉素市场预计将从 2025 年的 4,710 吨成长到 2031 年的 6,640 吨，复合年增长率为 5.89%。

作为一种频谱大环内酯类抗生素，阿奇霉素广泛用于治疗轻度至中度细菌感染疾病，特别适用于皮肤、软组织和呼吸系统感染。市场成长的主要驱动力是全球性行为感染感染疾病和社区型肺炎发病率的上升，这些疾病需要价格合理且容易取得的治疗方案。此外，该药物优异的药物动力学特性，使其能够每日一次给药并缩短疗程，从而提高患者依从性，并维持成人和儿童患者群体的强劲需求。例如，美国疾病管制与预防中心 (CDC) 报告称，2024 年美国将开出约 3,630 万张阿奇霉素处方笺。

儘管市场需求稳定，但日益严重的抗生素抗药性给市场带来了巨大挑战，对长期发展构成威胁。大环内酯类抗生素的滥用加剧了抗药性菌株的扩散，迫使医疗机构转向其他抗生素，从而有效缩小了阿奇霉素产品的市场规模。抗药性细菌带来的压力，加上旨在限制不必要抗生素使用的监管倡议，共同构成了全球阿奇霉素二水合物产业持续成长的障碍。

市场驱动因素

细菌性呼吸道感染疾病的日益增多是全球阿奇霉素二水合物市场的主要驱动因素，推动了这种广谱频谱的持续销售量成长。肺炎链球菌和霉浆菌等病原体是社区流行性肺炎的常见原因，而阿奇霉素起效迅速、通讯协定短，因此在临床实践中仍被广泛依赖。这种高需求量往往超过产能，导致间歇性供不应求，凸显了该药物的重要性。根据美国食品药物管理局（FDA）2025年9月发布的公告，某些阿奇霉素製剂已被列入FDA的药品短缺资料库，显示由于呼吸道治疗的持续需求，该药物存在严重的供应短缺。

同时，需要使用抗生素治疗的性行为感染（STI）病例的增加显着推高了市场需求，尤其是淋病和披衣菌感染的治疗方法。阿奇霉素的单剂量特性显着提高了患者在性健康护理中的用药依从性，巩固了其在开发中国家和已开发国家作为标准治疗药物的地位。根据美国疾病管制与预防中心（CDC）于2025年9月发布的《2024年性行为感染监测报告》，2024年美国报告的性行为感染病例超过220万例，处方率居高不下。英国卫生安全局（UKHSA）在其2025年6月发布的报告《UKHSA发布最新性行为感染数据》中进一步凸显了这一问题的全球性严重性，报告指出，2024年英格兰的淋病诊断病例数达到71,802例，证实了抗生素治疗的广泛需求。

市场挑战

抗生素抗药性的日益严重限制了全球阿奇霉素二水合物市场的成长，因为它降低了药物的临床疗效，迫使人们转向其他疗法。随着细菌病原体对大环内酯类抗生素的敏感性降低，卫生部门被迫更新标准治疗通讯协定，这往往导致阿奇霉素不再是治疗感染疾病和性行为感染感染等常见疾病的第一线药物。这种临床和监管重点的转变直接减少了阿奇霉素的处方量，并缩小了其目标患者群体，因为医疗专业人员会选择其他类别的抗生素以确保可靠的治疗效果。

近期监测数据显示抗药性菌株迅速传播，印证了这一趋势的影响。世界卫生组织（WHO）预测，到2025年，淋病奈瑟菌分离株对阿奇霉素的抗药性率将从2022年的0.5%上升至2024年的4%。这项疗效降低的统计证据支持合理使用抗菌药物的概念，即限制大环内酯类抗生素的使用，以减缓抗药性的进一步发展。因此，疗效降低和更严格的处方指南共同构成了全球阿奇霉素二水合物市场销售成长的持续障碍。

市场趋势

随着製药公司积极减少对单一来源关键抗生素前驱物的依赖，全球原料药（API）供应链的策略多元化正在重塑市场格局。这一趋势的特点是，尤其是在印度，生产奖励显着转向区域性，以抵消地缘政治风险并确保关键大环内酯类药物的供应安全。各国政府正在建立强而有力的金融框架，以促进关键起始原料（KSM）的国内生产，这些原料过去主要依赖从中国进口。根据2025年5月《eHealth》杂誌题为「政府征集生产关联激励计划（PLI）下的新申请以促进国内原料药生产」的报道，印度药品管理局已向国内生产商分配了总合1600吨的硫氰酸红霉素（阿奇霉素合成的关键前体）产能，以降低进口依赖。

同时，随着产业领导者将环境责任置于优先地位，以应对源自工业废弃物的抗生素抗药性细菌的蔓延，永续绿色化学製造的采用正在加速。製造商正积极利用酵素法製程和先进的废弃物管理系统，以减少抗生素残留物流入水道，并满足日益严格的国际环境标准。这种营运模式的转变不仅解决了生态系统问题，还透过减少合成和发酵过程中的公用设施消耗和碳足迹，提高了效率。根据Centrient Pharmaceuticals于2025年6月发布的《2024年ESG报告》，该公司已成功将其范围1和范围2的温室气体排放在2024年较2022年的基准值降低了8%，这充分体现了该行业对永续生产方式的切实承诺。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球阿奇霉素二水合物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品细分（原料药级阿奇霉素二水合物、药用级阿奇霉素二水合物、科研级阿奇霉素二水合物）
  • 依用途（抗生素、呼吸道感染疾病、性行为感染感染、皮肤感染疾病）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美阿奇霉素二水合物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲阿奇霉素二水合物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区二水合阿奇霉素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲阿奇霉素二水合物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美阿奇霉素二水合物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球二水合阿奇霉素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Azithromycin Dihydrate Market is projected to expand from 4.71 Thousand Tonnes in 2025 to 6.64 Thousand Tonnes by 2031, registering a compound annual growth rate of 5.89%. Functioning as a broad-spectrum macrolide antibiotic, this pharmaceutical is extensively prescribed for mild to moderate bacterial infections, specifically those impacting the skin, soft tissues, and respiratory tract. The market's trajectory is primarily propelled by the growing worldwide incidence of sexually transmitted infections and community-acquired pneumonia, which demand affordable and accessible therapeutic solutions. Additionally, the drug's advantageous pharmacokinetic profile-enabling once-daily dosing and shorter treatment durations-bolsters patient adherence and maintains robust demand across adult and pediatric populations. Highlighting this dominance, the Centers for Disease Control and Prevention reported that in 2024, approximately 36.3 million outpatient prescriptions for azithromycin were dispensed in the United States.

Despite this steady demand, the market encounters significant obstacles stemming from increasing antimicrobial resistance, which poses a threat to long-term development. The spread of resistant bacterial strains, aggravated by the overuse of macrolides, necessitates that healthcare providers transition toward alternative antibiotic classes, effectively shrinking the accessible market for azithromycin products. This pressure from resistance, coupled with regulatory stewardship initiatives designed to limit unnecessary antibiotic intake, creates an enduring impediment to the sustained volumetric expansion of the global azithromycin dihydrate industry.

Market Driver

The rising prevalence of bacterial respiratory tract infections acts as the central engine for the Global Azithromycin Dihydrate Market, fueling continuous volume growth for this broad-spectrum macrolide. Because pathogens like Streptococcus pneumoniae and Mycoplasma pneumoniae are frequent causes of widespread community-acquired pneumonia, clinical dependence on azithromycin persists due to its rapid effectiveness and brief treatment protocols. This elevated consumption often exceeds production capacities, resulting in intermittent availability issues that highlight the drug's critical nature. According to the U.S. Food and Drug Administration in September 2025, specific azithromycin formulations were listed in the agency's drug shortage database, signaling the intense supply strain driven by these enduring respiratory treatment requirements.

Simultaneously, the growing burden of sexually transmitted infections (STIs) requiring antibiotic intervention significantly reinforces market demand, especially for gonorrhea and chlamydia treatment regimens. Azithromycin's single-dose capability provides a vital benefit for patient compliance within sexual health initiatives, cementing its role as a standard therapy in both developing and developed nations. According to the Centers for Disease Control and Prevention's 'Sexually Transmitted Infections Surveillance, 2024' report released in September 2025, over 2.2 million reportable STI cases were recorded in the United States in 2024, maintaining high prescription rates. Underscoring the global scale of this issue, the UK Health Security Agency noted in its 'UKHSA publishes latest STI data' from June 2025 that gonorrhoea diagnoses in England reached 71,802 in 2024, confirming the extensive need for antibiotic intervention.

Market Challenge

The rise of antimicrobial resistance presents a formidable constraint to the growth of the Global Azithromycin Dihydrate Market by diminishing the drug's clinical effectiveness and forcing a transition to alternative treatments. As bacterial pathogens exhibit lower susceptibility to macrolides, health authorities are increasingly obligated to update standard treatment protocols, frequently removing azithromycin from its position as a first-line therapy for prevalent conditions like respiratory tract infections and sexually transmitted infections. This shift in clinical and regulatory focus directly reduces prescription quantities, as practitioners select other antibiotic classes to guarantee successful outcomes, thereby narrowing the addressable patient population for azithromycin formulations.

Recent surveillance data underscoring the swift spread of resistant strains substantiates the impact of this trend. According to the World Health Organization in 2025, resistance to azithromycin within Neisseria gonorrhoeae isolates increased globally from 0.5% in 2022 to 4% in 2024. Such statistical proof of reduced efficacy supports antibiotic stewardship programs that limit macrolide use to postpone further resistance development. Consequently, the convergence of declining therapeutic efficacy and stricter prescribing guidelines forms a lasting obstacle to the volume growth of the global azithromycin dihydrate sector.

Market Trends

The strategic diversification of global API supply chains is transforming the market as pharmaceutical firms actively decrease their reliance on single-source producers for essential antibiotic precursors. This movement is defined by a notable pivot toward localized manufacturing incentives, especially within India, to offset geopolitical risks and guarantee the security of critical macrolide supplies. Governments are establishing strong financial structures to promote the domestic production of Key Starting Materials (KSMs) that were previously imported primarily from China. According to eHealth Magazine's May 2025 report, 'Govt Invites Fresh Applications Under PLI Scheme to Boost Domestic Bulk Drug Production,' the Indian Department of Pharmaceuticals assigned a combined production capacity of 1,600 metric tons for Erythromycin Thiocyanate, the main precursor for azithromycin synthesis, to domestic manufacturers to limit import dependence.

Concurrently, the adoption of sustainable green chemistry manufacturing is gathering momentum as industry leaders prioritize environmental responsibility to fight the dissemination of antimicrobial resistance caused by industrial waste. Manufacturers are increasingly utilizing enzymatic methods and advanced waste management systems to limit the release of antibiotic residues into waterways, complying with stricter global environmental standards. This operational shift not only tackles ecological issues but also improves efficiency by lowering utility usage and carbon footprints during synthesis and fermentation. According to Centrient Pharmaceuticals' 'ESG Report 2024' released in June 2025, the company achieved an 8% reduction in its Scope 1 and 2 greenhouse gas emissions in 2024 against its 2022 baseline, demonstrating the sector's concrete dedication to sustainable production methods.

Key Market Players

• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan N.V

Report Scope

In this report, the Global Azithromycin Dihydrate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Azithromycin Dihydrate Market, By Product

• API Grade Azithromycin Dihydrate
• Pharmaceutical Grade Azithromycin Dihydrate
• Research Grade Azithromycin Dihydrate

Azithromycin Dihydrate Market, By Application

• Antibiotics
• Respiratory Infections
• Sexually Transmitted Diseases
• Skin Infections

Azithromycin Dihydrate Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Azithromycin Dihydrate Market.

Available Customizations:

Global Azithromycin Dihydrate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Azithromycin Dihydrate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (API Grade Azithromycin Dihydrate, Pharmaceutical Grade Azithromycin Dihydrate, Research Grade Azithromycin Dihydrate)
  • 5.2.2. By Application (Antibiotics, Respiratory Infections, Sexually Transmitted Diseases, Skin Infections)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Azithromycin Dihydrate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Azithromycin Dihydrate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Azithromycin Dihydrate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Azithromycin Dihydrate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Azithromycin Dihydrate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Azithromycin Dihydrate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. France Azithromycin Dihydrate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Azithromycin Dihydrate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Azithromycin Dihydrate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Azithromycin Dihydrate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Azithromycin Dihydrate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Azithromycin Dihydrate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Azithromycin Dihydrate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Azithromycin Dihydrate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Azithromycin Dihydrate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Azithromycin Dihydrate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. Middle East & Africa Azithromycin Dihydrate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Azithromycin Dihydrate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Azithromycin Dihydrate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Azithromycin Dihydrate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. South America Azithromycin Dihydrate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Azithromycin Dihydrate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Azithromycin Dihydrate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Azithromycin Dihydrate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Azithromycin Dihydrate Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sandoz International GmbH
• 15.4. Arbindo Pharma Limited
• 15.5. Mylan N.V

16. Strategic Recommendations

17. About Us & Disclaimer